Gilead Sciences-partnered Arcus Biosciences stocks plummeted, reversing 287% gain, due to failed cancer regimen.
The stock of Arcus Biosciences experienced a significant drop on Friday, erasing a previous gain of almost 300%, following the failure of its cancer treatment collaboration with Gilead Sciences. This reversal marked an end to the company's eight-month winning streak, causing a notable impact on its financial standing.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments